Last 20 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -13.04 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | 31.88 | — | — | — | — | 28.44 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 7.66 | 10.79 | 5.09 | 4.95 | 5.51 | 3.72 | 3.45 | 5.25 | 3.30 | 2.41 | 2.13 | 1.25 | 0.87 |
| — | +189.7% | +47.8% | -5.6% | +66.9% | +54.5% | +61.8% | +320.9% | +278.2% | +137.1% | +95.2% | -26.3% | -57.7% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | — | — | — | — | 100.0% | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | -205.2% | — | — | — | — | -513.3% | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | -174.2% | — | — | — | — | -537.5% | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -73.9% | -17.0% | -13.8% | -6.6% | -24.7% | -10.8% | -17.5% | -16.9% | -14.9% | -14.4% | -8.7% | -16.1% | -12.2% |
| — | -56.8% | +21.1% | +60.6% | -66.3% | +24.9% | -99.8% | -4.6% | -22.1% | -6.1% | +39.2% | -43.7% | — | |
| ROA | -50.3% | -11.7% | -9.9% | -4.7% | -18.8% | -8.4% | -12.1% | -11.1% | -10.0% | -10.0% | -6.2% | -12.0% | -9.3% |
| — | -38.3% | +18.1% | +57.2% | -87.9% | +15.9% | -93.0% | +7.6% | -6.8% | +6.8% | +46.7% | -33.0% | — | |
| ROIC | -91.8% | -10.2% | -10.0% | -8.6% | -34.5% | -16.0% | -15.4% | -14.4% | -14.5% | -15.6% | -21.4% | -57.8% | -725.4% |
| — | +36.1% | +34.9% | +40.1% | -138.0% | -2.5% | +28.2% | +75.1% | +98.0% | — | +97.1% | +84.8% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 50.9% YoY to 10.57x, tightening the short-term liquidity position. Debt/Equity has risen for 5 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.29 | 0.39 | 0.34 | 0.31 | 0.29 | 0.17 | 0.30 | 0.40 | 0.36 | 0.32 | 0.30 | 0.28 | 0.21 |
| — | +131.0% | +14.8% | -23.6% | -18.5% | -47.3% | -0.4% | +44.3% | +72.4% | +76.0% | +86.8% | +78.0% | +34.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 9.25 | 10.57 | 10.12 | 14.37 | 9.25 | 21.52 | 13.29 | 10.37 | 8.00 | 9.51 | 10.35 | 12.95 | 11.42 |
| — | -50.9% | -23.9% | +38.6% | +15.6% | +126.3% | +28.4% | -19.9% | -29.9% | -23.8% | -33.1% | -39.4% | -55.3% | |
| Quick Ratio | 9.25 | 10.57 | 10.12 | 14.37 | 9.25 | 21.52 | 13.29 | 10.37 | 8.00 | 9.51 | 10.35 | 12.56 | 11.42 |
| — | -50.9% | -23.9% | +38.6% | +15.6% | +126.3% | +28.4% | -17.4% | -29.9% | -22.4% | -31.5% | -40.0% | -55.3% | |
| Interest Coverage | -19.93 | -18.61 | -18.95 | -10.70 | -30.08 | -18.15 | -17.42 | -14.27 | -13.69 | -15.82 | -19.19 | -20.84 | -19.23 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 20 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCentessa Pharmaceuticals plc's current P/E is -13.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Centessa Pharmaceuticals plc's business trajectory between earnings reports.